Jounce Therapeutics, Inc.

JNCE · NASDAQ
Analyze with AI
12/31/2022
9/30/2022
6/30/2022
3/31/2022
Operating Activities
Net Income$50,959-$30,998-$33,513-$37,367
Dep. & Amort.$442$495$560$590
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,441$2,560$2,443$2,829
Change in WC$5,247-$3,728$6,882$481
Other Non-Cash$145$131$223$301
Operating Cash Flow$59,234-$31,540-$23,405-$33,166
Investing Activities
PP&E Inv.-$223-$240-$349-$107
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0-$24,928
Inv. Sales/Matur.$14,450$31,150$41,050$22,675
Other Inv. Act.$0$0$0$0
Investing Cash Flow$14,227$30,910$40,701-$2,360
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$442$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$442$0$33$409
Financing Cash Flow$0$0$33$409
Forex Effect$0$0$0$0
Net Chg. in Cash$73,461-$630$17,329-$35,117
Supplemental Information
Beg. Cash$78,381$79,011$61,682$96,799
End Cash$151,842$78,381$79,011$61,682
Free Cash Flow$59,011-$31,780-$23,754-$33,273